- Home
- CYBN vs TNXP Comparison
CYBN vs TNXP Comparison
Compare CYBN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- TNXP
- Stock Information
- Founded
- CYBN 2019
- TNXP 2007
- Country
- CYBN Canada
- TNXP United States
- Employees
- CYBN N/A
- TNXP N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- TNXP Health Care
- Exchange
- CYBN Nasdaq
- TNXP Nasdaq
- Market Cap
- CYBN 174.9M
- TNXP 207.5M
- IPO Year
- CYBN N/A
- TNXP N/A
- Fundamental
- Price
- CYBN $7.71
- TNXP $33.33
- Analyst Decision
- CYBN Strong Buy
- TNXP Strong Buy
- Analyst Count
- CYBN 4
- TNXP 2
- Target Price
- CYBN $86.00
- TNXP $585.00
- AVG Volume (30 Days)
- CYBN 310.7K
- TNXP 1.1M
- Earning Date
- CYBN 08-07-2025
- TNXP 08-15-2025
- Dividend Yield
- CYBN N/A
- TNXP N/A
- EPS Growth
- CYBN N/A
- TNXP N/A
- EPS
- CYBN N/A
- TNXP N/A
- Revenue
- CYBN N/A
- TNXP $10,041,000.00
- Revenue This Year
- CYBN N/A
- TNXP $11.66
- Revenue Next Year
- CYBN N/A
- TNXP $793.18
- P/E Ratio
- CYBN N/A
- TNXP N/A
- Revenue Growth
- CYBN N/A
- TNXP N/A
- 52 Week Low
- CYBN $4.81
- TNXP $6.76
- 52 Week High
- CYBN $13.88
- TNXP $137.25
- Technical
- Relative Strength Index (RSI)
- CYBN 50.59
- TNXP 52.50
- Support Level
- CYBN $7.50
- TNXP $33.41
- Resistance Level
- CYBN $9.20
- TNXP $37.42
- Average True Range (ATR)
- CYBN 0.56
- TNXP 3.48
- MACD
- CYBN -0.12
- TNXP -1.12
- Stochastic Oscillator
- CYBN 27.06
- TNXP 33.66
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.